TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
Globe Newswire•29/07/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.